GlassScriptPhysician profile
Derrell D Deloach
NPI 1548284433
$7,241.68
in general payments reported to CMS, 2019-2025
50 companies · $642 in 2025
The $642 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,885 · 2022: $1,439 · 2023: $1,727 · 2024: $1,549 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $624.41 | 2021-2024 | |
| Glaxosmithkline, LLC. | $521.01 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $500.82 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $438.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $387.03 | 2021-2024 | Xarelto, Spravato |
| Pfizer INC. | $380.36 | 2021-2024 | |
| Amgen INC. | $359.80 | 2021-2025 | Evenity, Prolia, Repatha |
| Axsome Therapeutics, INC. | $356.56 | 2023-2024 | Auvelity |
| Novo Nordisk INC | $325.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $292.55 | 2021-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $286.03 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $273.66 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.73 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $168.63 | 2023-2024 | Livalo, Seglentis, Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.05 | 2021-2024 | Jardiance |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $157.86 | 2021-2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $154.05 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.03 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $118.38 | 2021 | |
| Lundbeck LLC | $107.32 | 2022-2024 | Rexulti |
| Tandem Diabetes Care, INC. | $92.37 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $91.53 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $84.23 | 2023-2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $81.65 | 2021-2023 | |
| Corcept Therapeutics | $72.52 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $71.71 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $71.40 | 2022-2025 | |
| Biogen, INC. | $66.46 | 2021-2022 | |
| Radius Health, INC. | $55.98 | 2021-2025 | Tymlos |
| Sequel Med Tech, LLC | $49.67 | 2025 | Twiist |
| Antares Pharma, INC. | $48.87 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Esperion Therapeutics, INC. | $46.67 | 2021 | |
| Idorsia Pharmaceuticals US INC | $46.60 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $39.77 | 2021 | |
| Mannkind Corporation | $37.98 | 2025 | |
| Phathom Pharmaceuticals, INC. | $35.57 | 2024 | Voquezna |
| Upsher-Smith Laboratories LLC | $30.55 | 2021 | |
| Bolton Medical INC | $30.15 | 2024 | Treo Abdominal Stent-Graft System |
| Halozyme INC | $29.64 | 2023 | |
| Neurocrine Biosciences, INC. | $29.26 | 2025 | |
| Ascendis Pharma Endocrinology INC | $28.81 | 2025 | Yorvipath |
| Beta Bionics, INC. | $23.71 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $22.62 | 2025 | Omnipod |
| Ibsa Pharma INC. | $19.33 | 2025 | Tirosint, Licart, Flector |
| Genentech USA, INC. | $19.29 | 2021 | |
| Horizon Therapeutics Plc | $15.79 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.78 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $14.84 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.68 | 2021 | |
| Optinose US, INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrell Deloach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.